Search

everythinglearnresearchcommunity

for

Search:↓

Further trials are needed to explore the efficacy of triamcinolone acetonide in dermatology.

Tofacitinib is effective and safe for elderly patients with ulcerative colitis.

Newborns with the common rash Erythema Toxicum have many active mast cells in their skin, but these cells don't produce the LL-37 peptide.

Longer immunotherapy treatment may improve outcomes for Merkel cell carcinoma patients.

A new mutation in the STING protein causes a disease with lupus-like symptoms and responds well to a specific inhibitor treatment.

Using tazarotene with GliSODin improves facial skin more than tazarotene alone.

ILC1-like cells can cause alopecia areata by affecting hair follicles.

Nail changes from immunotherapy can be managed without stopping cancer treatment.

Some patients receiving pegylated interferon alfa injections developed skin necrosis, requiring treatment adjustments or discontinuation.

Tofacitinib helps improve skin conditions in people with Down syndrome, especially alopecia areata.

Triamcinolone acetonide and betamethasone 1.75 mg/ml are both effective for treating alopecia areata.

IFN-γ production by CD4 T cells is crucial for causing alopecia areata.

Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.

Adding Triamcinolone to the tumescent solution is more effective in preventing post-operative swelling after hair transplants.

The girl's scalp infection healed well with terbinafine treatment.

A 16-year-old boy's facial condition improved with doxycycline, suggesting an immune response to hair follicle damage.

CTCL patients can safely continue treatment during COVID-19 with proper safety measures.

Tofacitinib may be effective for treating hair loss caused by alopecia areata that doesn't respond to other treatments.

Immune therapy for cancer can cause rare hair loss but doesn't stop treatment success.

The study found that sweat glands normally suppress immune responses, but this is disrupted in certain skin diseases, possibly contributing to their development.

Intralesional triamcinolone acetonide effectively treats acne keloidalis nuchae with minimal side effects.

Tofacitinib partially improved hair regrowth in a patient with severe hair loss.

A young woman with lupus developed tuberculosis due to weakened immunity from her medication, showing the need for better TB screening in such patients.

Targeted immune modulation can help achieve stable remission in alopecia areata.

Some patients on immune therapy for melanoma may develop scarring hair loss, but cancer treatment remains effective.

A man's skin condition was misdiagnosed and later identified as a rare type of skin cancer, which did not improve with treatment.

Two men experienced hair regrowth while being treated with immune globulin for other health issues, but there were also side effects.

CGRP may help protect hair follicles from immune system attacks, potentially slowing hair loss.